Взаимозаменяемость анти-PD1 препаратов как инструмент реагирования на сложные условия финансирования
Автор: Федянин М.Ю., Кравчук Д.Г., Моисенко Ф.В., Агранов И.Р., Борщев Г.Г., Попов Д.В., Глазкова Е.В., Евдокимов В.И., Чубенко В.А., Левченко Е.Н., Волков Н.М.
Журнал: Злокачественные опухоли @malignanttumors
Статья в выпуске: 3S1 т.13, 2023 года.
Бесплатный доступ
Короткий адрес: https://sciup.org/140302069
IDR: 140302069 | DOI: 10.18027/2224-5057-2023-13-3s1-4-6
Список литературы Взаимозаменяемость анти-PD1 препаратов как инструмент реагирования на сложные условия финансирования
- Assessment report OPDIVO International non-proprietary name: Nivolumab. London: European Medicines Agency 2015.
- EMA. Assessment report Keytruda International non-propri-etary name: pembrolizumab 2015.
- Имянитов ЕН., «Отличия пролголимаба от других ингибиторов контрольных точек иммунного ответа». VI Петербургский Международный онкологический форум «Белые ночи», 25-28 июня 2020.
- Zak KM, Kitel R, Przetocka S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 2015 ; 23: 2341-8.
- Tyulyandin SA, Fedyanin MYu, Semiglazova TYu, et al. BCD-100-first Russian PD-1 inhibitor. Journal of Modern Oncology. 2017 ; 19 (3): 5-12.
- Centanni M, Moes DJAR, Trocóniz IF, et al. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019 Jul ; 58 (7): 835-857.
- Liu S-Y, Huang W-C, Yeh H-I, et al. Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity - from case report to mouse model validation. Cancers 2019, 11 (4), 580.
- Liang X, Guan Y, Zhang B, et al. Severe immune-related pneumonitis with PD-1 inhibitor after progression on previous PD-L1 inhibitor in small cell lung cancer: A case report and review of the literature. Front Oncol. 2019 ; 9: 1437.
- Lepir T, Zaghouani M, Roche SP,, et al. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report. Medicine (Baltimore). 2019 Jan ; 98 (2): e13804.
- Martini DJ, Lalani A-KA, Bossé D, et al. Response to single agent PD-1 inhibitor after progression on previous PD-1 / PD-L1 inhibitors: a case series. J Immunother Cancer. 2017 Aug 15 ; 5 (1): 66.
- Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thorac Cancer. 2020 Jul ; 11 (7): 1927-1933.
- Zaremba A, Eggermont A, Robert C, Dummer RR, et al.The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients, European Journal of Cancer, Volume 155, 2021, Pages 268-280.
- Abou AS et al. Safety and efficacy of restarting immune check-point inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020 Feb ; 8 (1): e000144.
- Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017 Mar ; 35 (7): 785-792.
- Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol 2015;22 (12): 953-8.
Статья
